Just - Evotec Biologics

NEWS
Bristol Myers Squibb is expanding its strategic collaboration with German partner Evotec for eight more years to discover and develop treatments for neurodegenerative diseases.
This week’s money flowed into various therapeutic areas like cancer and inflammatory disorders, while government and philanthropic grants fund the fight against infectious diseases.
Evotec and Sernova partnered to develop an implantable induced pluripotent stem cell (iPSC)-based beta cell replacement therapy that can be used to treat both type 1 and 2 diabetes patients.
Evotec SE announced that the strategic transaction to acquire Just Biotherapeutics, signed on 20 May 2019, has been completed.
The deal will grow Evotec’s business into a comprehensive offering including biologics in therapeutic areas such as oncology, CNS, pain, inflammation, metabolics and infectious diseases.
Evotec SE announced the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. (“Just.Bio”), for up to $ 90 m including potential performance-based earn-out components expected within the next three years.
Evotec SE announced today the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. (“Just.Bio”) based in Seattle, WA, USA for up to US$ 90 m (approx. EUR 81 m; EUR/$ fx rate of 1.117) including potential performance-based earn-out components expected within the next three years.
IN THE PRESS
Evotec SE announced that the Company entered a partnership with Inserm, the French National Institute of Health and Medical Research, Lille University Hospital and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases.
Evotec SE has announced the extension of its 20-year collaboration with CHDI Foundation, Inc. CHDI is a privately funded nonprofit biomedical research organisation exclusively dedicated to collaboratively developing therapeutics that will substantially improve the lives of those affected by Huntington’s disease.
Evotec SE announced financial results and corporate updates for the first quarter 2024.
Evotec SE will announce its financial results for the first quarter of 2024 on Wednesday, 22 May 2024.
Bayer and the German-based life science company, Evotec, announced that they have updated the focus of their strategic collaboration to developing innovative precision treatments for cardiovascular diseases.
Evotec SE reported financial results and corporate updates for the fiscal year ended 31 December 2023 and announced a priority reset to optimise its business to meet evolving market demand and focus on profitable growth in 2024 and beyond.
The Supervisory Board of Evotec SE has appointed Dr Christian Wojczewski as the Company’s new Chief Executive Officer, effective 01 July 2024.
Evotec SE is going to hold a conference call to provide a statement as well as a business update on Monday, 22 January 2024.
Evotec SE announced its financial results and corporate updates for the first half-year of 2023.
Evotec SE announces that it is adjusting its guidance for the fiscal year 2023.